Anaxis Pharma is an Australian Biotech company developing novel inhibitors / modulators of cell death, specifically necroptosis, an inflammatory form of programmed cell death. This process, involving both kinases and pseudokinases, is central to and dysregulated in chronic inflammatory disease. Targeting necroptosis fulfils an unmet medical need for patients with diseases including irritable bowel disease, Crohn’s disease, liver fibrosis and reperfusion injury. As an innovative joint venture between Synthesis Research and the Walter and Eliza Hall Institute of Medical Research, we leverage the extensive expertise and capabilities of the Institute, with the medicinal chemistry experience available to SYNthesis Research. Anaxis Pharma delivers on complex medicinal chemistry campaigns focused on hit-to-lead, lead optimisation and preclinical drug candidate selection. Anaxis has been able to attract funding from major pharma for two of its pre-clinical programs and is now uniquely positioned to rapidly advance their partnered programs to the clinic.